Future therapies for pre-eclampsia: Beyond treading water

Australian and New Zealand Journal of Obstetrics and Gynaecology

Volumn 54, Issue 1, 2014, Pages 3-8

  Fenton, Christine ^a   Hobson, Sebastian R ^b   Wallace, Euan M ^a,b   Lim, Rebecca ^a,b  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

endothelium; inflammation; oxidative stress; placenta; pre eclampsia

Indexed keywords

ENDOTHELIUM; INFLAMMATION; OXIDATIVE STRESS; PLACENTA; PRE-ECLAMPSIA;

ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INFLAMMATION; PRE-ECLAMPSIA; PREGNANCY;

EID: 84895066056     PISSN: 00048666     EISSN: 1479828X     Source Type: Journal    
DOI: 10.1111/ajo.12134     Document Type: Review

References (54)

1. Ghulmiyyah L, Sibai B,. Maternal mortality from preeclampsia/eclampsia. Semin Perinatol 2012; 36 (1): 56-59.
2. Payne B, Magee LA, von Dadelszen P,. Assessment, surveillance and prognosis in pre-eclampsia. Best Pract Res Clin Obstet Gynaecol 2011; 25 (4): 449-462.
3. Lowe SA, Brown MA, Dekker G, et al,. Guidelines for the management of hypertensive disorders of pregnancy, (2008). SOMANZ. Available from URL: www.somanz.org/pdfs/somanz-guidelines-2008 (accessed 21 September 2013).
4. Raymond D, Peterson E,. A critical review of early-onset and late-onset preeclampsia. Obstet Gynecol Surv 2011; 66 (8): 497-506.
5. Podymow T, August P,. Antihypertensive drugs in pregnancy. Semin Nephrol 2011; 31 (1): 70-85.
6. Roberts JM, Taylor RN, Musci TJ, et al,. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989; 161 (5): 1200-1204.
7. Roberts JM, Hubel CA,. The two stage model of preeclampsia: variations on the theme. Placenta 2009; 30 (Suppl A): S32-S37.
8. Karumanchi SA, Maynard SE, Stillman IE, et al,. Preeclampsia: a renal perspective. Kidney Int 2005; 67 (6): 2101-2113.
9. Redman CW, Sacks GP, Sargent IL,. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999; 180 (2 Pt 1): 499-506.
10. Hladunewich M, Karumanchi SA, Lafayette R,. Pathophysiology of the clinical manifestations of preeclampsia. Clin J Am Soc Nephrol 2007; 2 (3): 543-549.
11. Wang A, Rana S, Karumanchi SA,. Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda) 2009; 24: 147-158.
12. Venkatesha S, Toporsian M, Lam C, et al,. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12 (6): 642-649.
13. Thadhani R, Kisner T, Hagmann H, et al,. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 2011; 124 (8): 940-950.
14. Moldenhauer JS, Stanek J, Warshak C, et al,. The frequency and severity of placental findings in women with preeclampsia are gestational age dependent. Am J Obstet Gynecol 2003; 189 (4): 1173-1177.
15. Dodd JM, McLeod A, Windrim RC, Kingdom J,. Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction. Cochrane Database Syst Rev 2010; (6): CD006780.
16. Hofmeyr GJ, Lawrie TA, Atallah AN, Duley L,. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev 2010; (8): CD001059.
17. Repke JT, Villar J, Anderson C, et al,. Biochemical changes associated with blood pressure reduction induced by calcium supplementation during pregnancy. Am J Obstet Gynecol 1989; 160 (3): 684-690.
18. Villar J, Repke JT,. Calcium supplementation during pregnancy may reduce preterm delivery in high-risk populations. Am J Obstet Gynecol 1990; 163 (4 Pt 1): 1124-1131.
19. Sacks GP, Studena K, Sargent K, Redman CW,. Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. Am J Obstet Gynecol 1998; 179 (1): 80-86.
20. LaMarca BB, Cockrell K, Sullivan E, et al,. Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant rats. Hypertension 2005; 46 (1): 82-86.
21. Crowther CA, Hiller JE, Moss JR, et al,. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 2005; 352 (24): 2477-2486.
22. Coomarasamy A, Honest H, Papaioannou S, et al,. Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review. Obstet Gynecol 2003; 101 (6): 1319-1332.
23. Duley L, Henderson-Smart DJ, Meher S, King JF,. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007; (2): CD004659.
24. Knight M, Duley L, Henderson-Smart DJ, King JF,. Antiplatelet agents for preventing and treating pre-eclampsia. Cochrane Database Syst Rev 2000; (2): CD000492.
25. Bonetti PO, Lerman LO, Napoli C, Lerman A,. Statin effects beyond lipid lowering-are they clinically relevant? Eur Heart J 2003; 24 (3): 225-248.
26. Costantine MM, Tamayo E, Lu F, et al,. Using pravastatin to improve the vascular reactivity in a mouse model of soluble fms-like tyrosine kinase-1-induced preeclampsia. Obstet Gynecol 2010; 116 (1): 114-120.
27. Kumasawa K, Ikawa M, Kidoya H, et al,. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci USA 2011; 108 (4): 1451-1455.
28. Ahmed A,. A proof of principle, double-blind, randomised placebo-controlled, multicentre trial of pravastatin to ameliorate early onset pre-eclampsia: ISRCTN Register; 2010 [Accessed 17 January 2013] Available from URL: http://www.controlled-trials.com/ISRCTN23410175
29. Baur JA, Sinclair DA,. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discovery 2006; 5 (6): 493-506.
30. Cudmore MJ, Ramma W, Cai M, et al,. Resveratrol inhibits the release of soluble fms-like tyrosine kinase (sFlt-1) from human placenta. Am J Obstet Gynecol 2012; 206 (3): 253, e10-5.
31. Sunderland NS, Thomson SE, Heffernan SJ, et al,. Tumor necrosis factor alpha induces a model of preeclampsia in pregnant baboons (Papio hamadryas). Cytokine 2011; 56 (2): 192-199.
32. El Mourabet M, El-Hachem S, Harrison JR, Binion DG,. Anti-TNF antibody therapy for inflammatory bowel disease during pregnancy: a clinical review. Curr Drug Targets 2010; 11 (2): 234-241.
33. Zhou CC, Zhang Y, Irani RA, et al,. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med 2008; 14 (8): 855-862.
34. Khamashta MA,. Systemic lupus erythematosus and pregnancy. Best Pract Res Clin Rheumatol 2006; 20 (4): 685-694.
35. Heilmann L, Schorsch M, Hahn T, Fareed J,. Antiphospholipid syndrome and pre-eclampsia. Semin Thromb Hemost 2011; 37 (2): 141-145.
36. Duckitt K, Harrington D,. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005; 330 (7491): 565.
37. Klonoff-Cohen HS, Savitz DA, Cefalo RC, McCann MF,. An epidemiologic study of contraception and preeclampsia. JAMA 1989; 262 (22): 3143-3147.
38. Wang JX, Knottnerus AM, Schuit G, et al,. Surgically obtained sperm, and risk of gestational hypertension and pre-eclampsia. Lancet 2002; 359 (9307): 673-674.
39. Tubbergen P, Lachmeijer AM, Althuisius SM, et al,. Change in paternity: a risk factor for preeclampsia in multiparous women? J Reprod Immunol 1999; 45 (1): 81-88.
40. Siddiqui AH, Irani RA, Blackwell SC, et al,. Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: correlation with disease severity. Hypertension 2010; 55 (2): 386-393.
41. Zhou CC, Irani RA, Zhang Y, et al,. Angiotensin receptor agonistic autoantibody-mediated tumor necrosis factor-alpha induction contributes to increased soluble endoglin production in preeclampsia. Circulation 2010; 121 (3): 436-444.
42. Roberts JM, Hubel CA,. Is oxidative stress the link in the two-stage model of pre-eclampsia? Lancet 1999; 354 (9181): 788-789.
43. Lindheimer MD, Sibai BM,. Antioxidant supplementation in pre-eclampsia. Lancet 2006; 367 (9517): 1119-1120.
44. Poston L, Briley AL, Seed PT, et al,. Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. Lancet 2006; 367 (9517): 1145-1154.
45. Lopez-Jaramillo P, Arenas WD, Garcia RG, et al,. The role of the L-arginine-nitric oxide pathway in preeclampsia. Ther Adv Cardiovasc Dis 2008; 2 (4): 261-275.
46. Dechend R, Viedt C, Muller DN, et al,. AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation 2003; 107 (12): 1632-1639.
47. Moreland RB, Goldstein II, Kim NN, Traish A,. Sildenafil Citrate, a Selective Phosphodiesterase Type 5 Inhibitor. Trends Endocrinol Metab 1999; 10 (3): 97-104.
48. Samangaya RA, Mires G, Shennan A, et al,. A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia. Hypertens Pregnancy 2009; 28 (4): 369-382.
49. Luizon MR, Sandrim VC,. Pharmacogenomic approaches that may guide preeclampsia therapy. Pharmacogenomics 2013; 14 (6): 591-593.
50. Bremer T, Man A, Kask K, Diamond C,. CACNA1C polymorphisms are associated with the efficacy of calcium channel blockers in the treatment of hypertension. Pharmacogenomics 2006; 7 (3): 271-279.
51. Zhao Y, Zhai D, He H, et al,. Effects of CYP3A5, MDR1 and CACNA1C polymorphisms on the oral disposition and response of nimodipine in a Chinese cohort. Eur J Clin Pharmacol 2009; 65 (6): 579-584.
52. Sandrim VC, Palei AC, Cavalli RC, et al,. eNOS haplotypes associated with gestational hypertension or preeclampsia. Pharmacogenomics 2008; 9 (10): 1467-1473.
53. Sandrim VC, Palei AC, Luizon MR, et al,. eNOS haplotypes affect the responsiveness to antihypertensive therapy in preeclampsia but not in gestational hypertension. Pharmacogenomics J 2010; 10 (1): 40-45.
54. Sadee W,. Pharmacogenomic biomarkers: validation needed for both the molecular genetic mechanism and clinical effect. Pharmacogenomics 2011; 12 (5): 675-680.